KLY.V - Kalytera Therapeutics, Inc.

TSXV - TSXV Delayed Price. Currency in CAD
Currency in CAD

Valuation Measures

Market Cap (intraday) 512.89M
Enterprise Value 316.04M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.78
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 3.02
52-Week Change 3-25.00%
S&P500 52-Week Change 35.18%
52 Week High 30.0600
52 Week Low 30.0100
50-Day Moving Average 30.0297
200-Day Moving Average 30.0314

Share Statistics

Avg Vol (3 month) 31.44M
Avg Vol (10 day) 3N/A
Shares Outstanding 5515.46M
Float 512.35M
% Held by Insiders 10.13%
% Held by Institutions 14.76%
Shares Short (Jun. 14, 2020) 4618.72k
Short Ratio (Jun. 14, 2020) 40.1
Short % of Float (Jun. 14, 2020) 4N/A
Short % of Shares Outstanding (Jun. 14, 2020) 40.05%
Shares Short (prior month May 14, 2020) 477.83k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:2
Last Split Date 3Jan. 10, 2017

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec. 30, 2018
Most Recent Quarter (mrq)Sep. 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-17.16%
Return on Equity (ttm)-191.78%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-11.55M
Diluted EPS (ttm)-0.0410
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)31k
Total Cash Per Share (mrq)0
Total Debt (mrq)3.18M
Total Debt/Equity (mrq)67.29
Current Ratio (mrq)0.14
Book Value Per Share (mrq)0.01

Cash Flow Statement

Operating Cash Flow (ttm)-7.15M
Levered Free Cash Flow (ttm)-1.8M